Journal: Archives of Medical Science : AMS

Article Title: Therapeutic potential of mesenchymal stem cells in cisplatin-induced acute kidney injury via ASK-1/TXNIP pathway modulation

doi: 10.5114/aoms/193707

Figure Lengend Snippet: Immunohistochemical staining of VEGF of renal cortex sections at magnification ×400, bar 25 µm. A – Immunohistochemical-stained kidney sections of control group showing strong reaction of VEGF protein expression in the renal cortex. B – Immunohistochemical-stained kidney sections of AKI group showing significant reduction in the expression of VEGF in renal medulla. C – Immunohistochemical-stained kidney sections for VEGF protein expression of FUR group showing mild increase in the expression of VEGF in renal cortex. D – Immunohistochemical-stained kidney sections for VEGF protein expression of MSCs group showing marked increase in the expression of VEGF in renal medulla E – The angiogenic effects of MSC in kidney tissue, expressed as area %. Data were presented as means ± SEM. Each column represented the means ± SEM. The mean variations between the groups using Turkey’s significant difference test. a p < 0.01 vs. control, b p < 0.01 vs. cisplatin induced acute kidney injury cells, c p < 0.01 vs. furosemide treated cells

Article Snippet: Hematoxylin and eosin (H&E) stain was applied to 5 μm sections of paraffin-embedded renal tissues for histological investigation [ ], using anti-VEGF rabbit polyclonal Ab (Boster Biological Technology, Pleasanton, CA, USA, Cat.# PA1080).

Techniques: Immunohistochemical staining, Staining, Control, Expressing

Journal: Stem Cell Research & Therapy

Article Title: Co-delivery of endometrial mesenchymal stem cells and macrophages by an electrospun patch promotes angiogenesis during endometrial injury repair via VEGF related signalling

doi: 10.1186/s13287-026-04929-2

Figure Lengend Snippet: Assessment of the tube formation capability, CD31 and VEGF gene expressions for HUVECs treated without (control) and with cell culture supernatant collected from H-EMSCs seeded on PCL-HA (PCL-HA/H-E) or H-EMSCs and mø co-seeded on PCL-HA (PCL-HA/H-E/mø). A Tube formation assay of HUVECs in the control, PCL-HA/H-E and PCL-HA/H-E/mø groups. Scale bar = 200 μm. B Quantification of the total length of the tubes formed. C Quantification of the total number of meshes formed. D Quantification of the number of nodes formed. E CD31 gene expression of the HUVECs. F VEGF gene expression of the HUVECs. *** p < 0.001. ## p < 0.01, ### p < 0.001 vs. Control

Article Snippet: The following lists the primary and secondary antibodies used: rabbit polyclonal to CD31 (1:200, 28083-1-AP, Proteintech); rabbit polyclonal to VEGF (1:200, PB9071, Boster); AlexaFluor ® 488 goat anti-mouse IgG (1:200, A28175, Thermo scientific) and AlexaFluor ® 568 goat anti-rabbit IgG (1:200, A-11011, Thermo scientific).

Techniques: Control, Cell Culture, Tube Formation Assay, Gene Expression

Journal: Stem Cell Research & Therapy

Article Title: Co-delivery of endometrial mesenchymal stem cells and macrophages by an electrospun patch promotes angiogenesis during endometrial injury repair via VEGF related signalling

doi: 10.1186/s13287-026-04929-2

Figure Lengend Snippet: Assessment of the tube formation capability, CD31 and VEGF gene expressions of HUVECs treated with cell culture supernatant collected from H-EMSCs seeded on PCL-HA (PCL-HA/H-E) or H-EMSCs and mø co-seeded on PCL-HA (PCL-HA/H-E/mø) or H-EMSCs and mø co-seeded on PCL-HA and VEGF inhibitor (PCL-HA/H-E/mø/VEGF inhibitor). A Tube formation assay of HUVECs in the PCL-HA/H-E, PCL-HA/H-E/mø and PCL-HA/H-E/mø/VEGF inhibitor groups. Scale bar = 200 μm. B Quantification of the total length of the tubes formed. C Quantification of the total number of meshes formed. D Quantification of the number of nodes formed. E CD31 gene expression of the HUVECs. F VEGF gene expression of the HUVECs. *** p < 0.001. # p < 0.05, ### p < 0.001 vs. PCL-HA/H-E group

Article Snippet: The following lists the primary and secondary antibodies used: rabbit polyclonal to CD31 (1:200, 28083-1-AP, Proteintech); rabbit polyclonal to VEGF (1:200, PB9071, Boster); AlexaFluor ® 488 goat anti-mouse IgG (1:200, A28175, Thermo scientific) and AlexaFluor ® 568 goat anti-rabbit IgG (1:200, A-11011, Thermo scientific).

Techniques: Cell Culture, Tube Formation Assay, Gene Expression

Journal: Stem Cell Research & Therapy

Article Title: Co-delivery of endometrial mesenchymal stem cells and macrophages by an electrospun patch promotes angiogenesis during endometrial injury repair via VEGF related signalling

doi: 10.1186/s13287-026-04929-2

Figure Lengend Snippet: VEGF, CD31 gene and protein expression of rat endometrial tissues of the PCL-HA/H-E, PCL-HA/H-E/mø and PCL-HA/H-E/mø/VEGF inhibitor groups at day 7. A VEGF gene expression. B Quantification of VEGF protein concentration (pg/ml). C Representative images of VEGF immunostaining. Cell nuclei stained in blue while VEGF stained in red. Scale bar = 100 μm. D Quantification of VEGF staining area (%). E CD31 gene expression. F Representative images of CD31 immunostaining. Cell nuclei stained in blue while CD31 stained in red. Scale bar = 100 μm. G Quantification of CD31 staining area (%). *** p < 0.001. ## p < 0.01, ### p < 0.001 vs. PCL-HA/H-E group

Article Snippet: The following lists the primary and secondary antibodies used: rabbit polyclonal to CD31 (1:200, 28083-1-AP, Proteintech); rabbit polyclonal to VEGF (1:200, PB9071, Boster); AlexaFluor ® 488 goat anti-mouse IgG (1:200, A28175, Thermo scientific) and AlexaFluor ® 568 goat anti-rabbit IgG (1:200, A-11011, Thermo scientific).

Techniques: Expressing, Gene Expression, Protein Concentration, Immunostaining, Staining

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: M. suaveolens extract blocked the expression of VEGF and NF-κB mRNA in lung tissue. Groups of mice were challenged with cecal ligation and puncture and treated with M. suaveolens extract 24 h later. The left lung tissues were homogenized and total RNA was extracted using TRIzol reagent and assayed by quantitative polymerase chain reaction. (A) Representative gels assessing (a) VEGF and (b) NF-κB levels are demonstrated. Lane 1, marker; lane 2, normal control group; lane 3, sham operation group; lane 4, (untreated) sepsis group and lane 5, treatment group. (B) Statistical summary of the densitometric analysis of VEGF and NF-κB mRNA expression in rats from the four groups; (a) VEGF mRNA and (b) NF-κB mRNA. Data are represented as the mean ± standard deviation of one experiment consisting of three replicates. ** P<0.01 vs. sham operation and normal control groups; ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Expressing, Ligation, Real-time Polymerase Chain Reaction, Marker, Control, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Effect of M. suaveolens extract on the expression of VEGF and NF-κB65 protein in lung tissue. Groups of mice were challenged with cecal ligation and puncture and treated with M. suaveolens extract 24 h later. The expression of VEGF, NF-κβ65 and GAPDH was detected by western blotting using specific antibodies. GAPDH protein was used an internal control. (A) Representative western blot analysis demonstrated the levels of VEGF and NF-κB65 protein expression in rats from the four groups; (a) normal control group; (b) sham operation group; (c) (untreated) sepsis group and (d) treatment group. (B) Quantification of the blots by densitometric analysis of (a) VEGF and (b) NF-κB65 protein expression in rats from the four groups. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. ** P<0.01 vs. the sham operation group and normal control group; # P<0.05 vs . (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Expressing, Ligation, Western Blot, Control, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Effect of M. suaveolens extract on the protein expression of VEGF and NF-κB65 in rat lungs 24 h following cecal ligation and puncture-induced acute lung injury. Immunostaining was performed on lung sections following antigen retrieval using Retrievagen. (A) Representative immunostaining revealed VEGF and NF-κβ65-positive expression in rats from the four groups: (a–c) Expression of positive VEGF in the (a) sham operation group; (b) control group; (c) treatment group); (d–f) Expression of positive NF-κB65 in the (d) sham operation group; (e) (untreated) sepsis group; (f) treatment group (magnification, ×200). (B) Quantification of the images by densitometric analysis of (a) VEGF and (b) NF-κB-positive protein expression in rats from four groups. All values are expressed as the mean ± standard deviation. ** P<0.01 vs. the sham operation group; ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Expressing, Ligation, Immunostaining, Control, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Effect of M. suaveolens extract on plasma levels of VEGF, TNF-α, IL-6, IL-1β, IL-4 and IL-10 levels in plasma. Groups of mice were challenged with cecal ligation and puncture, and treated with M. suaveolens extract 24 h later. (A) VEGF, (B) TNF-α, (C) IL-6, (D) IL-1β, (E) IL-10 and (F) IL-4 levels in plasma were determined by ELISA. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. * P<0.05, ** P<0.01 vs. the sham operation group and normal control group; # P<0.05, ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B; TNF-α, tumor necrosis factor-α; IL, interleukin.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Clinical Proteomics, Ligation, Enzyme-linked Immunosorbent Assay, Standard Deviation, Control

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Administration of M. suaveolens extract attenuated lipopolysaccharide-induced pulmonary inflammation. Groups of mice were challenged with cecal ligation and puncture, and treated with M. suaveolens extract 24 h later. (A) VEGF, (B) TNF-α, (C) IL-6, (D) IL-1β, (E) IL-10 and (F) IL-4 levels in bronchoalveolar lavage were determined by ELISA. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. ** P<0.01 vs. the sham operation group and normal control group; # P<0.05, ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B; TNF-α, tumor necrosis factor-α; IL, interleukin.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Ligation, Enzyme-linked Immunosorbent Assay, Standard Deviation, Control

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Administration of M. suaveolens extract reduces CLP-induced lung permeability. Rats were treated as indicated and (A) FITC-labeled albumin in the bronchoalveolar lavage fluid, (B) water content of lung tissue and (C) W/D lung weight ratio were determined 24 h following CLP challenge. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. * P<0.05, ** P<0.01 vs. the sham operation and normal control groups; ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B; TNF-α, tumor necrosis factor-α; IL, interleukin; CLP, cecal ligation and puncture; W/D, wet/dry; FITC, fluorescein isothiocyanate.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Permeability, Labeling, Standard Deviation, Control, Ligation